{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T16:15:54Z","timestamp":1772813754618,"version":"3.50.1"},"reference-count":38,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2006,8,31]],"date-time":"2006-08-31T00:00:00Z","timestamp":1156982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2006,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>In vitro studies have shown synergistic or additive interactions between rituximab and purine nucleoside analogues. The results of recent clinical trials seem to confirm these preclinical observations.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>For the current study, the authors evaluated the feasibility, efficacy, and toxicity of combined regimens that consisted of either rituximab plus cladribine (2\u2010CdA) (the RC regimen) or RC plus cyclophosphamide (the RCC regimen) in the treatment of patients with heavily pretreated, indolent lymphoid malignancies. Fifty\u2010four adult patients with recurrent or refractory, low\u2010grade non\u2010Hodgkin lymphoma (LG\u2010NHL) and B\u2010cell chronic lymphocytic leukemia (B\u2010CLL) were treated according to the RC\/RCC regimens. The RC protocol consisted of intravenous rituximab at a dose of 375 mg\/m<jats:sup>2<\/jats:sup> on Day 1 and 2\u2010CdA at a dose of .12 mg\/kg per day on Days 2 through 6. The RCC protocol consisted of rituximab at a dose of 375 mg\/m<jats:sup>2<\/jats:sup> on Day 1, 2\u2010CdA at a dose of 0.12 mg\/m<jats:sup>2<\/jats:sup> on Days 2 through 4, and intravenous cyclophosphamide at a dose of 250 mg\/m<jats:sup>2<\/jats:sup> per day on Days 2 to 4. The RC\/RCC courses were repeated at 4\u2010week intervals.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Thirty\u2010three patients with B\u2010CLL, 12 patients with LG\u2010NHL and 9 patients with mantle cell lymphoma (MCL) entered the study. Thirty\u2010three patients (61%) had recurrent disease after prior therapy, and 21 patients (39%) had refractory disease. Thirty\u2010one patients were treated on the RC regimen, and 23 patients were treated on the RCC regimen. Six patients (11%) achieved a complete response, and 33 patients (60%) achieved a partial response. The median failure\u2010free survival of responders was 10.5 months. The treatment revealed tolerability, with episodes of severe neutropenia (Grade 3 and 4 [according to World Health Organization criteria]) observed in 6 patients (11%), episodes of Grade 3 and 4 infections observed in 11 patients (20%), and episodes of Grade 3\u20104 thrombocytopenia observed in 4 patients (7%).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>The RC and RCC regimens were highly effective and well tolerated modalities of treatment in heavily pretreated patients with indolent lymphoproliferative disorders. Cancer 2006. \u00a9 2006 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.22196","type":"journal-article","created":{"date-parts":[[2006,8,31]],"date-time":"2006-08-31T16:50:58Z","timestamp":1157043058000},"page":"1542-1550","source":"Crossref","is-referenced-by-count":42,"title":["Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma"],"prefix":"10.1002","volume":"107","author":[{"given":"Tadeusz","family":"Robak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Smolewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Cebula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Szmigielska\u2010Kaplon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Chojnowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerzy Z.","family":"Blonski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,9,18]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.7.2463.2463"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402531"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402639"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000139666"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.2165\/00024669-200504050-00001"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03014.x"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/13693780400007151"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.516"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.051"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.172"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0796"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.3836"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/1042819032000159825"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200522120-00002"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.100"},{"issue":"1","key":"e_1_2_5_17_2","first-page":"100a","article-title":"Combination chemotherapy with pentostatin, cyclophosphamide and rituximab induces high rate of remissions including complete responses and achievement of minimal residual disease in previously untreated chronic lymphocytic leukemia","volume":"104","author":"Kay E","year":"2004","journal-title":"Blood."},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3835"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V46.2.219.219"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.2307\/2531951"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199709109163"},{"key":"e_1_2_5_24_2","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1200\/JCO.1994.12.4.788","article-title":"2\u2010Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non\u2010Hodgkin's lymphoma","volume":"12","author":"Hoffman M","year":"1994","journal-title":"J Clin Oncol."},{"key":"e_1_2_5_25_2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3109\/10428199709114170","article-title":"Intermittent infusion of cladribine (CdA) in previously treated patients with low\u2010grade non\u2010Hodgkin's lymphoma","volume":"25","author":"Liliemark J","year":"1997","journal-title":"Leuk Lymphoma."},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690195"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2001.00303.x"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1159\/000087251"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1080\/1042819021000046958"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1323"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20820"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21535"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2003.n.026"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008325110921"},{"issue":"1","key":"e_1_2_5_36_2","first-page":"1111","article-title":"Cladribine (CdA) or fludarabine (F) or high\u2010dose intermittent chlorambucil (Chl) as first\u2010line treatment in chronic lymphocytic leukemia: first interim analysis of data from the international randomized Phase III trial","volume":"104","author":"Karlsson K","year":"2004","journal-title":"Blood."},{"issue":"2","key":"e_1_2_5_37_2","first-page":"600a","article-title":"Randomized comparison of cladribine with cyclophosphamide and fludarabine with cyclophosphamide in previously untreated progressive and symptomatic chronic lymphocytic leukemia: the interim analysis of PALG CLL3 trial","volume":"106","author":"Robak T","year":"2005","journal-title":"Blood."},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2395"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-4828"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.22196","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.22196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T16:54:24Z","timestamp":1760288064000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.22196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,18]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["10.1002\/cncr.22196"],"URL":"https:\/\/doi.org\/10.1002\/cncr.22196","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9,18]]}}}